Cencora stock sets fiscal 2027 outlook after strong finish

Cencora reported its fiscal fourth-quarter and full-year results on Wednesday, November 4, after the fiscal year ended September 30. The pharmaceutical distributor posted higher revenue, stronger adjusted earnings and a fiscal 2027 outlook that puts specialty services at the center of its growth plan. The figures were published in the Cencora investor relations release.

Cencora stock traded at 304.25 euros on Lang & Schwarz at 16:06 CET on Wednesday, November 4, 2026.

Quarterly profit gains momentum

Fourth-quarter revenue increased 5.5 percent year over year to 88.4 billion US dollars. GAAP diluted earnings per share came in at 2.71 US dollars, compared with a loss of 1.75 US dollars in the prior-year quarter. Adjusted diluted earnings per share rose 21.4 percent to 4.66 US dollars.

Adjusted operating income increased 22.1 percent to 1.2 billion US dollars. Cencora said the February acquisition of OneOncology supported gross-profit growth, while higher operating expenses partly offset that contribution. The comparison also benefited from a 723.9 million US dollar PharmaLex goodwill impairment charge in the prior-year quarter.

Fiscal 2027 targets take shape

For fiscal 2027, Cencora expects revenue growth of 3 to 5 percent and adjusted operating-income growth of 4 to 6 percent. Adjusted diluted earnings per share are expected in a range of 19.40 to 19.75 US dollars, compared with 17.97 US dollars in fiscal 2026.

The company will report under three segments from the first quarter of fiscal 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. Management expects the specialty segment to deliver adjusted operating-income growth of 18 to 21 percent, ahead of the 2 to 4 percent target for Pharmaceutical Distribution and Services.

Capital returns and next steps

Cencora declared a quarterly dividend of 0.66 US dollars per share on November 3, up 10 percent from 0.60 US dollars. The dividend is payable on November 30 to shareholders of record on November 13.

For investors, the new guidance shifts attention from the fiscal-year recovery in GAAP earnings toward execution under the revised structure, the OneOncology integration and the planned transactions involving Profarma and MWI Animal Health. The company reaffirmed long-term targets for adjusted operating-income growth of 7 to 10 percent and adjusted diluted earnings-per-share growth of 10 to 14 percent.

Cencora stock is part of the US healthcare market, where the S&P 500 remains a broad reference for large-cap investor sentiment.

For more news and analyses on Cencora stock, follow the company topic page.